The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results.
Jon Glass
No relevant relationships to disclose
Minhee Won
No relevant relationships to disclose
Christopher J. Schultz
No relevant relationships to disclose
Daniel Brat
No relevant relationships to disclose
Nancy Bartlett
No relevant relationships to disclose
John H. Suh
Consultant or Advisory Role - Abbott Laboratories
Barbara Jean Fisher
No relevant relationships to disclose
Marcia K. Liepman
No relevant relationships to disclose
Minesh P. Mehta
Employment or Leadership Position - Pharmacyclics
Consultant or Advisory Role - Merck
Stock Ownership - Pharmacyclics
Honoraria - Merck